Gallium-68 PSMA-11 PET in Intermediate to High-risk Preprostatectomy Patients
Status:
Completed
Trial end date:
2019-12-31
Target enrollment:
Participant gender:
Summary
The investigators are imaging patients with prostate cancer using a new PET imaging agent
(Ga-68-PSMA-11) in order to evaluate it's ability to detection prostate cancer in patients
with high risk disease prior to prostatectomy.